Frederik Keus

Frederik Keus

Auto-generated profile, based on publicly available information

Frederik Keus

Department of Critical Care University Medical Center Groningen, University of Groningen Groningen The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2019 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
PDF file
BKBritt E. Keuning
Britt E. Keuning
TKThomas Kaufmann
Thomas Kaufmann
RWRenske Wiersema
Renske Wiersema
AGAnders Granholm
Anders Granholm
VPVille Pettilä
Ville Pettilä
HCHEALICS consortium
HEALICS consortium
Background: Mortality prediction models are applied in the intensive care unit (ICU) to stratify patients into different risk categories and to facilitate benchmarking. To ensure that the correct prediction models are applied for these purposes, the best performing models must be identified. As a first step, we aimed to establish a systematic review of mortality prediction models in critically ill patients.Methods: Mortality prediction models were searched in four databases using the following criteria: developed for use in adult ICU patients in high‐income countries, with mortality as primary or secondary outcome. Characteristics and performance measures of the models were summarized. Performance was presented in terms of discrimination, calibration and overall performance measures presented in the original publication.Results: In total, 43 mortality prediction models were included in the final analysis. In all, 15 models were only internally validated (35%), 13 externally (30%) and 10 (23%) were both internally and externally validated by the original researchers. Discrimination was assessed in 42 models (98%). Commonly used calibration measures were the Hosmer‐Lemeshow test (60%) and the calibration plot (28%). Calibration was not assessed in 11 models (26%). Overall performance was assessed in the Brier score (19%) and the Nagelkerke's R2 (4.7%).Conclusions: Mortality prediction models have varying methodology, and validation and performance of individual models differ. External validation by the original researchers is often lacking and head‐to‐head comparisons are urgently needed to identify the best performing mortality prediction models for guiding clinical care and research in different settings and populations.

4 July 2022 in BMJ
Verified
Journal Article
Open access
PDF file
RERuben J. Eck
Ruben J. Eck
TETessa Elling
Tessa Elling
ASAlex J Sutton
Alex J Sutton
JWJørn Wetterslev
Jørn Wetterslev
CGChristian Nyfeldt Gluud
Christian Nyfeldt Gluud
FKFrederik Keus
Frederik Keus
Objective To assess the benefits and harms of different types and doses of anticoagulant drugs for the prevention of venous thromboembolism in patients who are acutely ill and admitted to hospital. Design Systematic review and network meta-analysis. Data sources Cochrane CENTRAL, PubMed/Medline, Embase, Web of Science, clinical trial registries, and national health authority databases. The search was last updated on 16 November 2021. Eligibility criteria for selecting studies Published and unpublished randomised controlled trials that evaluated low or intermediate dose low-molecular-weight heparin, low or intermediate dose unfractionated heparin, direct oral anticoagulants, pentasaccharides, placebo, or no intervention for the prevention of venous thromboembolism in acutely ill adult patients in hospital. Main outcome measures Random effects, bayesian network meta-analyses used four co-primary outcomes: all cause mortality, symptomatic venous thromboembolism, major bleeding, and serious adverse events at or closest timing to 90 days. Risk of bias was also assessed using the Cochrane risk-of-bias 2.0 tool. The quality of evidence was graded using the Confidence in Network Meta-Analysis framework. Results 44 randomised controlled trials that randomly assigned 90 095 participants were included in the main analysis. Evidence of low to moderate quality suggested none of the interventions reduced all cause mortality compared with placebo. Pentasaccharides (odds ratio 0.32, 95% credible interval 0.08 to 1.07), intermediate dose low-molecular-weight heparin (0.66, 0.46 to 0.93), direct oral anticoagulants (0.68, 0.33 to 1.34), and intermediate dose unfractionated heparin (0.71, 0.43 to 1.19) were most likely to reduce symptomatic venous thromboembolism (very low to low quality evidence). Intermediate dose unfractionated heparin (2.63, 1.00 to 6.21) and direct oral anticoagulants (2.31, 0.82 to 6.47) were most likely to increase major bleeding (low to moderate quality evidence). No conclusive differences were noted between interventions regarding serious adverse events (very low to low quality evidence). When compared with no intervention instead of placebo, all active interventions did more favourably with regard to risk of venous thromboembolism and mortality, and less favourably with regard to risk of major bleeding. The results were robust in prespecified sensitivity and subgroup analyses. Conclusions Low-molecular-weight heparin in an intermediate dose appears to confer the best balance of benefits and harms for prevention of venous thromboembolism. Unfractionated heparin, in particular the intermediate dose, and direct oral anticoagulants had the least favourable profile. A systematic discrepancy was noted in intervention effects that depended on whether placebo or no intervention was the reference treatment. Main limitations of this study include the quality of the evidence, which was generally low to moderate due to imprecision and within-study bias, and statistical inconsistency, which was addressed post hoc. Systematic review registration PROSPERO CRD42020173088.

12 January 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
RERuben J. Eck
Ruben J. Eck
LHLisa Hulshof
Lisa Hulshof
RWRenske Wiersema
Renske Wiersema
ETEpidemiology H.L. Thio
Epidemiology H.L. Thio
BHBart Hiemstra
Bart Hiemstra
FKFrederik Keus
Frederik Keus
Background: The objective of this study was to describe the prevalence, incidence, prognostic factors, and outcomes of venous thromboembolism in critically ill patients receiving contemporary thrombosis prophylaxis. Methods: We conducted a pooled analysis of two prospective cohort studies. The outcomes of interest were in-hospital pulmonary embolism or lower extremity deep vein thrombosis (PE-LDVT), in-hospital nonleg deep vein thrombosis (NLDVT), and 90-day mortality. Multivariable logistic regression analysis was used to evaluate the association between predefined baseline prognostic factors and PE-LDVT or NLDVT. Cox regression analysis was used to evaluate the association between PE-LDVT or NLDVT and 90-day mortality. Results: A total of 2208 patients were included. The prevalence of any venous thromboembolism during 3 months before ICU admission was 3.6% (95% CI 2.8–4.4%). Out of 2166 patients, 47 (2.2%; 95% CI 1.6–2.9%) developed PE-LDVT and 38 patients (1.8%; 95% CI 1.2–2.4%) developed NLDVT. Renal replacement therapy (OR 3.5 95% CI 1.4–8.6), respiratory failure (OR 2.0; 95% CI 1.1–3.8), and previous VTE (OR 3.6; 95% CI 1.7–7.7) were associated with PE-LDVT. Central venous catheters (OR 5.4; 95% CI 1.7–17.8) and infection (OR 2.2; 95% CI 1.1–4.3) were associated with NLDVT. Occurrence of PE-LDVT but not NLDVT was associated with increased 90-day mortality (HR 2.7; 95% CI 1.6–4.6, respectively, 0.92; 95% CI 0.41–2.1). Conclusion: Thrombotic events are common in critically ill patients, both before and after ICU admittance. Development of PE-LDVT but not NLDVT was associated with increased mortality. Prognostic factors for developing PE-LDVT or NLDVT despite prophylaxis can be identified at ICU admission and may be used to select patients at higher risk in future randomized clinical trials. Trial registration: NCT03773939.

18 March 2019 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
PDF file
OSOlav L. Schjørring
Olav L. Schjørring
APAnders Perner
Anders Perner
JWJørn Wetterslev
Jørn Wetterslev
TLTheis Lange
Theis Lange
FKFrederik Keus
Frederik Keus
TIthe HOT-ICU Investigators
the HOT-ICU Investigators
Background: Acutely ill adults with hypoxaemic respiratory failure are at risk of life‐threatening hypoxia, and thus oxygen is often administered liberally. Excessive oxygen use may, however, increase the number of serious adverse events, including death. Establishing the optimal oxygenation level is important as existing evidence is of low quality. We hypothesise that targeting an arterial partial pressure of oxygen (PaO2) of 8 kPa is superior to targeting a PaO2 of 12 kPa in adult intensive care unit (ICU) patients with acute hypoxaemic respiratory failure.Methods: The Handling Oxygenation Targets in the ICU (HOT‐ICU) trial is an outcome assessment blinded, multicentre, randomised, parallel‐group trial targeting PaO2 in acutely ill adults with hypoxaemic respiratory failure within 12 hours after ICU admission. Patients are randomised 1:1 to one of the two PaO2 targets throughout ICU stay until a maximum of 90 days. The primary outcome is 90‐day mortality. Secondary outcomes are serious adverse events in the ICU, days alive without organ support and days alive out of hospital in the 90‐day period; mortality, health‐related quality‐of‐life at 1‐year follow‐up as well as 1‐year cognitive and pulmonary function in a subgroup; and an overall health economic analysis. To detect or reject a 20% relative risk reduction, we aim to include 2928 patients. An interim analysis is planned after 90‐day follow‐up of 1464 patients.Conclusion: The HOT‐ICU trial will test the hypothesis that a lower oxygenation target reduces 90‐day mortality compared with a higher oxygenation target in adult ICU patients with acute hypoxaemic respiratory failure.

12 June 2017 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
MKM. Krag
M. Krag
APA. Perner
A. Perner
JWJ. Wetterslev
J. Wetterslev
TLT. Lange
T. Lange
MWM. P. Wise
M. P. Wise
MMM. H. Møller
M. H. Møller

18 February 2020 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
OSOlav Lilleholt Schjørring
Olav Lilleholt Schjørring
TKThomas Lass Klitgaard
Thomas Lass Klitgaard
APAnders Perner
Anders Perner
JWJørn Wetterslev
Jørn Wetterslev
TLTheis Lange
Theis Lange
BRBodil Steen Rasmussen
Bodil Steen Rasmussen